Pancreatic cancer remains a major unsolved health problem, with conventional cancer
treatments having little impact on disease course. Almost all patients who have pancreatic …

It is not an exaggeration to state that most of the advances in curing cancer in the last
decade have come from successful combinations of conventional chemotherapeutic agents …

Purpose To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated
with dose-escalated intensity modulated radiation therapy (IMRT) with curative intent …

Purpose The purpose of this trial was to evaluate the role of radiation therapy with
concurrent gemcitabine (GEM) compared with GEM alone in patients with localized …

PURPOSE AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built
on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with …

Purpose: Investigate the efficacy and pharmacodynamic effects of MK-1775, a potent Wee1
inhibitor, in both monotherapy and in combination with gemcitabine (GEM) using a panel of …

The median survival for patients with locally advanced pancreatic cancer treated with
gemcitabine and radiation is approximately 1 year. To develop improved treatment, we have …

PURPOSE: Fractionated radiotherapy and chemotherapy for locally advanced pancreatic
cancer achieves only modest local control. This prospective trial evaluated the efficacy of a …

PURPOSE: This Phase II trial evaluated the toxicity, local control, and overall survival in
patients treated with sequential gemcitabine and linear accelerator–based single-fraction …

I n the United States there are 28,000 to 30,300 newly diagnosed cases of pancreatic cancer
and approximately an equal number of deaths per year from pancreatic cancer. 1, 2 Ductal …